Last week’s EPRA conference provided cautious optimism on listed European real estate. The segment offers a mix of risks and opportunities, with discounted valuations presenting attractive entry points. We downgrade Care Property Invest (Underperform vs Neutral, TP €12 vs €13.5); we lower our TPs for British Land, Landsec, Shurgard, and Xior Student Housing; we raise our TPs for URW, Wereldhave and VGP. In conclusion we favour logistics, retail, Spain, and CEE for growth, and Switzerland remains...
Yesterday, UCB hosted an R&D call to dive into the 3-year data for Bimzelx in hidradenitis suppurativa (HS), presented last week at EADV 2025, which showed sustained or deepening HiSCR responses. Draining tunnel count continued to decline, improving quality of life, with DLQI 0/1 responses continuing to increase up to 148 weeks. KOLs John Ingram and Amit Garg favoured Bimzelx over other therapies incl. IL-17, citing its depth of response and real-world efficacy, and highlighted the need for earl...
Years before its BaseCamp bid (May'22), Xior invested in a bold Dutch residential pipeline. It acquired mainly old offices for conversion. These projects were iced as its LTV hit emergency levels in 2023. With LTV now below 50%, these non-yielding assets can be developed at a very gradual pace. Despite the dire shortage in the Dutch residential market, the political situation and regulations delay and limit returns on these investments. However, the cost-to-come for some of these projects is rel...
ASM hosts Investor Day, provides new 2030 targets, revises H2 2025 outlook Almere, The Netherlands September 23, 2025, 7:45 a.m. CET ASM International N.V. (Euronext Amsterdam: ASM) today hosts its 2025 Investor Day in London. In today’s presentations, Hichem M’Saad, CEO, and Paul Verhagen, CFO, together with other senior leaders, will provide updates on our business, financial performance, and market outlook, and lay out our strategic priorities through 2030. Hichem M’Saad, CEO of ASM, said: “The semiconductor market is on track to reach US$1 trillion by the end of the decade, driven...
HEINEKEN to acquire FIFCO’s beverage and retail businesses, strengthening its presence across Central America HEINEKEN to acquire FIFCO’s beverage and retail businesses, strengthening its presence across Central America Landmark acquisition accelerates growth with leading beverage portfolio and retail assets in Costa Rica, full ownership of HEINEKEN Panama, and expanded regional footprint HEINEKEN has entered into binding agreements with its long-term partner FIFCO to acquire the remaining 75% of Distribuidora La Florida, as well as FIFCO stakes in certain other businesses.The transaction...
We refresh our ING Benelux Favourites list. We apply a fundamental bottom up approach in which we select stocks that provide the best (relative) upside within our Benelux coverage universe and these stocks need clear catalysts. Besides this, we screen the ING Benelux coverage on key investment themes that are topical and which provide insights into the relative risk-reward of the individual stocks, which could affect earnings potential and thus a stock's share price performance: (1) we screen ou...
UCB announced new 12-week efficacy and 18-week safety data from the phase 1/2a first-in-patient trial for galvokimig (IL-13, IL-17A and IL-17F antibody) in moderate-to-severe atopic dermatitis, to be presented at EADV 2025. The results showed a 52.6% placebo adjusted response on the primary endpoint of =75% improvement from baseline in Eczema Area and Severity Index (EASI75). We view this as competitive compared to other phase 2 trials in atopic dermatitis, and highlight competitor Dupixent's $ ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.